Two Japanese Textile Firms Expand Pharmaceutical Businesses
This article was originally published in PharmAsia News
Executive Summary
Two Japanese textile companies are expanding their pharmaceutical holdings as one way to guard against bad economic times. Asahi Kasei plans to expand one of its facilities specializing in drug compounds at a cost of about $10.4 million. Toray Industries says it will double the capacity of one of its plants to produce tablets and capsules as early as autumn, including Toray's anti-itch drug for dialysis patients, currently outsourced. (Click here for more - a subscription may be required
You may also be interested in...
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.